N. Ngogianghuong et al., MUTATIONS IN RESIDUE-61 OF H-RAS P21-PROTEIN INFLUENCE MHC CLASS-II PRESENTATION, International immunology, 7(2), 1995, pp. 269-275
We have investigated the influence of mutations in the Ras 61 codon on
the immunogenicity of synthetic peptides and H-Ras p21 proteins. H-2(
k) mice produced Th responses when immunized with mutated peptides in
which the Gln at position 61 in the wild type sequence was replaced by
Leu (L) or His (H). T cell hybridomas specific for the 61L and 61H pe
ptides were then produced. The responses of both were I-A(k) restricte
d. Competition experiments indicated that the wild type peptide did no
t bind to the I-A(k) molecule whereas the two mutations generated a si
te on the peptides that was agretopic for the I-A(k) molecule. Neverth
eless the recognition of the corresponding Has proteins was highly dep
endent upon the nature of the substitution. The H-Ras p21 protein with
the 61L mutation (61L) was processed by syngeneic splenocytes and the
epitope dependent on 61L was recognized as efficiently as the corresp
onding peptide by the T cell hybridoma specific for 61L. In contrast,
the processing of H-Ras p21 with the 61H mutation (61H) was probably i
nefficient in producing the epitope recognized by the hybridoma specif
ic for 61H. Furthermore, immunization studies with the two mutated H-R
as p21 proteins suggest that only the 61L substitution can be exploite
d for immunotherapy. Thus this work demonstrates that any peptide immu
notherapy must be undertaken with the reservation that not all oncogen
ic mutations at codon 61 will be amenable to immune therapy.